Johnson & JohnsonJNJ

Johnson & Johnson shared new results from a two-year study of nipocalimab, a treatment for generalized myasthenia gravis. This rare condition causes the immune system to attack the body's own muscles, leading to severe weakness. The data showed that patients, including teenagers, maintained better muscle strength and daily function over the long term while being able to take fewer corticosteroids, which are often used for the condition but carry heavy side effects.

This is a positive step for J&J as it tries to build a new multi-billion dollar franchise in immunology, which is the study of the immune system. Success here is important because the company is looking for new sources of growth to replace revenue from older drugs that are losing their patent protection.

Source: PRNewsWire

New data from a long-term study shows that half of patients with a specific type of blood cancer remained in remission five years after a single infusion of Carvykti. The results suggest that using this cell therapy, which re-engineers a patient's own immune cells to fight cancer, earlier in the treatment process can lead to much longer periods without the disease returning.

This strengthens the case for Carvykti becoming a standard treatment for patients who have only tried one or two other therapies. For the company, this is a critical piece of its oncology business. Success here helps support the goal of making this therapy a multibillion-dollar driver of growth over the next several years.

Source: PRNewsWire

Johnson & Johnson reported that its drug Tremfya met all main goals in a study of patients with axial psoriatic arthritis, a condition that causes inflammation in the spine and joints. It is the first treatment in its specific class, known as IL-23 inhibitors, to prove it can reduce spinal pain and stiffness using MRI scans to confirm the results.

This is a win for the company as it works to expand how many conditions Tremfya can treat. The drug is a key part of the plan to grow revenue as older blockbusters lose their patent protection. Proving it works for spinal symptoms helps it compete more effectively against other treatments in the crowded immunology market.

Source: PRNewsWire

A new study shows that patients with a type of blood cancer called multiple myeloma who were treated with a combination of Tecvayli and Darzalex Faspro had a similar risk of death to the general population. This benefit was driven by a 90 percent reduction in the risk of the cancer getting worse compared to the current standard treatments.

This is important because Darzalex is already a multibillion-dollar drug for the company, and finding ways to use it earlier in a patient's treatment cycle helps protect its revenue. As the company faces the loss of patent protection on other older drugs, proving that its newer treatments can fundamentally change how long patients live is key to keeping its lead in the cancer market.

Source: PRNewsWire

Johnson & Johnson reported that a late-stage trial for Caplyta met its primary goal, showing the drug was effective at treating adults with bipolar mania. The drug is already approved for other conditions, but this successful study moves it closer to being used for a broader range of psychiatric needs.

Expanding the uses for existing drugs is a key part of how the company plans to grow its medicine business. If regulators approve this new use, it would add another steady source of revenue to help offset the loss of patent protection on older blockbuster treatments.

Source: Reuters

Metrics we are tracking